EPRX

Healthcare Biotechnology

Eupraxia Pharmaceuticals Inc.

$7.86

+0.11 +1.42% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 6, 2026, live at 2:30 PM ET	7.86

Key Stats

Market Cap

519.01M

Avg Volume

532,775

EPS

-$1.02

52W High

$9.32

52W Low

$5.25

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-7.57

P/B Ratio

5.05

EV/EBITDA

-7.15

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(66.7%)

Return on Assets

(43.7%)

Liquidity & Leverage

Current Ratio

16.00

Quick Ratio

15.71

Debt / Equity

0.01

Total Cash

133.66M

Total Debt

1.84M

About

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.